BC Week In Review | Apr 4, 2011
Clinical News

Dexpramipexole: Phase III started

Biogen Idec began the double-blind, placebo-controlled, international Phase III EMPOWER trial to evaluate 150 mg dexpramipexole twice daily for up to 18 months in about 804 ALS patients. The trial start triggered a $10 million...
BioCentury | Jan 3, 2011
Strategy

Biogen's aggregation play

Biogen Idec Inc. 's purchase of three preclinical mAbs from Neurimmune Therapeutics AG is a bet on a new theory of neurodegenerative disease in which extracellular forms of aggregated proteins spread disease throughout the brain,...
BioCentury | Nov 8, 2010
Strategy

Ring fencing MS

In the spring of 2009, Carl Icahn argued that Biogen Idec Inc. should be split into two companies, one focused on neurology and the other oncology. In the company's restructuring last week, new CEO George...
BC Week In Review | Oct 25, 2010
Company News

Knopp Neurosciences neurology news

Knopp Neurosciences transferred all assets, excluding dexpramipexole (KNS-760704), to new parent entity, Knopp Biosciences LLC , which will focus on expanding its drug discovery capabilities, including research activities directed at mitochondrial mechanisms of neurodegeneration and other...
BioCentury | Aug 30, 2010
Finance

Knopp Gives Back

Knopp gives back After licensing its only clinical candidate to Biogen Idec Inc. (NASDAQ:BIIB), Knopp Neurosciences Inc. decided it could afford to give a dividend to investors. Knopp granted Biogen Idec an exclusive, worldwide license...
BC Week In Review | Aug 23, 2010
Company News

Knopp Neurosciences, Biogen Idec deal

Knopp granted Biogen Idec an exclusive, worldwide license to develop and commercialize dexpramipexole (KNS-760704). The small modulator of mitochondrial bioenergetics with an unknown target, is slated to enter Phase III testing or amyotrophic lateral sclerosis...
BioCentury | Aug 23, 2010
Finance

Regulatory milestones

Celgene Corp. (NASDAQ:CELG) shed $2 to $53.67 last week after Japan's Ministry of Health, Labor and Welfare approved Revlimid lenalidomide to treat myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion. In June, Japan approved...
BC Extra | Aug 18, 2010
Company News

Biogen Idec, Knopp in ALS deal

Knopp Neurosciences Inc. (Pittsburgh, Pa.) granted Biogen Idec Inc. (NASDAQ:BIIB) exclusive, worldwide rights to develop and commercialize dexpramipexole ( KNS-760704 ). The small modulator of mitochondrial bioenergetics with an unknown target, is slated to begin Phase...
BC Week In Review | Apr 26, 2010
Clinical News

Dexpramipexole: Additional Phase II data

A post hoc analysis of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 150 and 300 mg/day KNS-760704 for 12 weeks displayed a significant dose-dependent trend in reducing treatment failure as measured by...
BC Week In Review | Dec 21, 2009
Clinical News

KNS-760704: Additional Phase II data

Additional data from 102 patients in Part 1 of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 100 and 300 mg KNS-760704 for 12 weeks displayed a dose-dependent trend in slowing the rate...
Items per page:
1 - 10 of 23
BC Week In Review | Apr 4, 2011
Clinical News

Dexpramipexole: Phase III started

Biogen Idec began the double-blind, placebo-controlled, international Phase III EMPOWER trial to evaluate 150 mg dexpramipexole twice daily for up to 18 months in about 804 ALS patients. The trial start triggered a $10 million...
BioCentury | Jan 3, 2011
Strategy

Biogen's aggregation play

Biogen Idec Inc. 's purchase of three preclinical mAbs from Neurimmune Therapeutics AG is a bet on a new theory of neurodegenerative disease in which extracellular forms of aggregated proteins spread disease throughout the brain,...
BioCentury | Nov 8, 2010
Strategy

Ring fencing MS

In the spring of 2009, Carl Icahn argued that Biogen Idec Inc. should be split into two companies, one focused on neurology and the other oncology. In the company's restructuring last week, new CEO George...
BC Week In Review | Oct 25, 2010
Company News

Knopp Neurosciences neurology news

Knopp Neurosciences transferred all assets, excluding dexpramipexole (KNS-760704), to new parent entity, Knopp Biosciences LLC , which will focus on expanding its drug discovery capabilities, including research activities directed at mitochondrial mechanisms of neurodegeneration and other...
BioCentury | Aug 30, 2010
Finance

Knopp Gives Back

Knopp gives back After licensing its only clinical candidate to Biogen Idec Inc. (NASDAQ:BIIB), Knopp Neurosciences Inc. decided it could afford to give a dividend to investors. Knopp granted Biogen Idec an exclusive, worldwide license...
BC Week In Review | Aug 23, 2010
Company News

Knopp Neurosciences, Biogen Idec deal

Knopp granted Biogen Idec an exclusive, worldwide license to develop and commercialize dexpramipexole (KNS-760704). The small modulator of mitochondrial bioenergetics with an unknown target, is slated to enter Phase III testing or amyotrophic lateral sclerosis...
BioCentury | Aug 23, 2010
Finance

Regulatory milestones

Celgene Corp. (NASDAQ:CELG) shed $2 to $53.67 last week after Japan's Ministry of Health, Labor and Welfare approved Revlimid lenalidomide to treat myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion. In June, Japan approved...
BC Extra | Aug 18, 2010
Company News

Biogen Idec, Knopp in ALS deal

Knopp Neurosciences Inc. (Pittsburgh, Pa.) granted Biogen Idec Inc. (NASDAQ:BIIB) exclusive, worldwide rights to develop and commercialize dexpramipexole ( KNS-760704 ). The small modulator of mitochondrial bioenergetics with an unknown target, is slated to begin Phase...
BC Week In Review | Apr 26, 2010
Clinical News

Dexpramipexole: Additional Phase II data

A post hoc analysis of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 150 and 300 mg/day KNS-760704 for 12 weeks displayed a significant dose-dependent trend in reducing treatment failure as measured by...
BC Week In Review | Dec 21, 2009
Clinical News

KNS-760704: Additional Phase II data

Additional data from 102 patients in Part 1 of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 100 and 300 mg KNS-760704 for 12 weeks displayed a dose-dependent trend in slowing the rate...
Items per page:
1 - 10 of 23